Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PD-L1 expression + REV3L overexpression
i
Other names:
REV3L, REV3 Like DNA Directed Polymerase Zeta Catalytic Subunit, POLZ, REV3, REV3-Like Polymerase (DNA Directed) Zeta Catalytic Subunit, DNA Polymerase Zeta Catalytic Subunit, REV3 (Yeast Homolog)-Like Catalytic Subunit Of DNA Polymerase Zeta, REV3-Like Catalytic Subunit Of DNA Polymerase Zeta (Yeast), Rev-3 Yeast Homolog-Like (Polymerase, DNA, Zeta), Protein Reversionless 3-Like, Polymerase DNA Zeta, REV3-Like, REV3L, HREV3, PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
29126
;
5980
Related biomarkers:
Expression
Mutation
CNA
Others
‹
NF1 L581Ffs*6 + KRAS A146P + NRAS Q61K + TP53 R175H + PD-L1 T290M (1)
PD-L1 rs1411262 (1)
PD-L1 rs2297136 (1)
PD-L1 rs4143815 (1)
PD-L1 rs822339 (1)
PD-L1 T290M (0)
PD-L1 mutation (0)
NF1 L581Ffs*6 + KRAS A146P + NRAS Q61K + TP53 R175H + PD-L1 T290M (1)
PD-L1 rs1411262 (1)
PD-L1 rs2297136 (1)
PD-L1 rs4143815 (1)
PD-L1 rs822339 (1)
PD-L1 T290M (0)
PD-L1 mutation (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
PD-L1 expression + REV3L overexpression
Urothelial Cancer
PD-L1 expression + REV3L overexpression
Urothelial Cancer
tislelizumab-jsgr
Resistant: C3 – Early Trials
tislelizumab-jsgr
Resistant
:
C3
tislelizumab-jsgr
Resistant: C3 – Early Trials
tislelizumab-jsgr
Resistant
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.